Effects of Adding Intravenous Pamidronate to Ongoing Menopausal Hormone Therapy in Postmenopausal Korean Women with Low Bone Mineral Density
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: We evaluated the effects of adding intravenous pamidronate to ongoing menopausal hormone therapy (MHT) on bone mineral density (BMD) in postmenopausal Korean women with low BMD. Methods: This retrospective cohort study included 74 postmenopausal women who received MHT for at least 1 year and had a BMD T-score of less than −2.0. Maintaining the same MHT regimen, these women were divided into two groups: oral placebo group (n = 44) and a pamidronate group of patients with gastrointestinal discomfort (n = 30) who received 15–30 mg pamidronate intravenously every 3–12 months. BMD was reviewed at 12-month follow-up. Bone resorption markers in both groups, urinary deoxypyridinoline levels in the placebo group, and serum N-telopeptide of type I collagen in the pamidronate group were assessed at 6 and 12 months. Results: At baseline, the body mass index (BMI), duration of previous MHT, and femur neck (FN) BMD differed between the groups. Within-group analysis revealed that BMD of the lumbar spine (LS) and total hip (TH) significantly increased in the placebo group, whereas those of the LS, FN, and TH increased in the pamidronate group. The increase in BMD of LS was significantly greater in the pamidronate group, after adjusting for BMI and duration of previous MHT (mean change: 3.7% vs. 6.2%; P < 0.001). There were no changes in bone resorption markers in either group. Conclusions: Adding intravenous pamidronate to ongoing MHT for 12 months might increase LS BMD in postmenopausal Korean women with low BMD.
Abstract
Objectives: We evaluated the effects of adding intravenous pamidronate to ongoing menopausal hormone therapy (MHT) on bone mineral density (BMD) in postmenopausal Korean women with low BMD. Methods: This retrospective cohort study included 74 postmenopausal women who received MHT for at least 1 year and had a BMD T-score of less than −2.0. Maintaining the same MHT regimen, these women were divided into two groups: oral placebo group (n = 44) and a pamidronate group of patients with gastrointestinal discomfort (n = 30) who received 15–30 mg pamidronate intravenously every 3–12 months. BMD was reviewed at 12-month follow-up. Bone resorption markers in both groups, urinary deoxypyridinoline levels in the placebo group, and serum N-telopeptide of type I collagen in the pamidronate group were assessed at 6 and 12 months. Results: At baseline, the body mass index (BMI), duration of previous MHT, and femur neck (FN) BMD differed between the groups. Within-group analysis revealed that BMD of the lumbar spine (LS) and total hip (TH) significantly increased in the placebo group, whereas those of the LS, FN, and TH increased in the pamidronate group. The increase in BMD of LS was significantly greater in the pamidronate group, after adjusting for BMI and duration of previous MHT (mean change: 3.7% vs. 6.2%; P < 0.001). There were no changes in bone resorption markers in either group. Conclusions: Adding intravenous pamidronate to ongoing MHT for 12 months might increase LS BMD in postmenopausal Korean women with low BMD.
참고문헌 (18)
- The Writing Group for the PEPI, "Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen", progestin interventions (PEPI) trial, 1996, pp.276, 1389~1396
- Nelson HD, "Osteoporosis and fractures in postmenopausal women using estrogen", Arch Intern Med, 162, pp.2278~2284 (2002)
- Hillard TC, "Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss", Osteoporos Int, 4, pp.341~348 (1994)
- Fleisch H, "Bisphosphonates : mechanisms of action", Endocr Rev, 19, pp.80~100 (1998)
- Black DM, "Fracture Intervention Trial Research Group", Lancet, 348, pp.1535~1541 (1996)
- Liberman UA, "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group", N Engl J Med, 333, pp.1437~1443 (1995)
- McClung MR, "Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group", N Engl J Med, 344, pp.333~340 (2001)
- Boonen S, "Effect of osteoporosis treatments on risk of non-vertebral fractures : review and metaanalysis of intention-to-treat studies", Osteoporos Int, 16, pp.1291~1298 (2005)
- Harris ST, "Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women", J Clin Endocrinol Metab, 86, pp.1890~1897 (2001)
- Min YK, "Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women : a randomized, doubleblind, placebo-controlled clinical trial", Menopause, 20, pp.761~766 (2013)
- SemihAki, "Gastrointestinal Side Effect Profile Due to the Use of Alendronate in the Treatment of Osteoporosis", Yonsei Medical Journal, 44(6), pp.961~967 (2003), 연세대학교의과대학
- Anckaert E, "Multicenter analytical performance evaluation of a fully automated anti-Müllerian hormone assay and reference interval determination", Clin Biochem, 49, pp.260~267 (2016)
- Reid IR, "Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis", J Clin Endocrinol Metab, 79, pp.1595~1599 (1994)
- Brumsen C, "Daily oral pamidronate in women and men with osteoporosis : a 3-year randomized placebo-controlled clinical trial with a 2-year open extension", J Bone Miner Res, 17, pp.1057~1064 (2002)
- Vis M, "The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis", Osteoporos Int, 16, pp.1432~1435 (2005)
- Kang M., "Textbook of osteoporosis", pp.253~265 (2016), Koonja
- Bae SJ, "Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates", J Bone Miner Metab, 30, pp.588~595 (2012)
- Drake MT, "Bisphosphonates : mechanism of action and role in clinical practice", Mayo Clin Proc, 83, pp.1032~1045 (2008)